The specialist cancer drug discovery and development business has announced final results for FY June 2015 with losses of £1.25m against our expectation of £1.5m largely due to the short term deferral of Clinical Trial Applications (CTA) for Checkpoint Kinase 1. The lead candidate in collaboration with the Cancer Research Technology Pioneer Fund will now be the subject of two CTAs in parallel seeking to test the molecule as a single agent in various cancer types as well as in comb
